Clinical trial
Efficacy of Bortezomib Consolidation After High-dose Melphalan With Stem Cell…
NCT00417911 · Nordic Myeloma Study Group, Other · Completed
Key facts
| NCT number | NCT00417911 |
|---|---|
| Title | Efficacy of Bortezomib Consolidation After High-dose Melphalan With Stem Cell Support in Myeloma Patients |
| Official title | Clinical Protocol Bortezomib Consolidation in Patients With Myeloma Following Treatment With High-dose Melphalan and Autologous Stem Cell Support. A Randomised NMSG Trial (15/05) |
| Lead sponsor | Nordic Myeloma Study Group, Other |
| Collaborators | Janssen-Cilag Ltd. Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Drug |
| Interventions | bortezomib |
| Enrollment | 400 |
| Start date | Dec 1, 2005 |
| Primary completion | May 1, 2009 |
| Completion | May 1, 2010 |
| First posted | Jan 4, 2007 |
| Last update posted | Jun 22, 2010 |
| Countries | Denmark, Finland, Iceland, Norway, Sweden |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: